Nymox Pursuing New Approaches to an Old Disease
Nymox Pharmaceutical Corporation is taking unique approaches to the diagnosis and treatment of Alzheimer's disease. Nymox's AD drug development programs focus on novel proprietary approaches to the diagnosis and treatment of Alzheimer's disease.
One such program targets spherons, tiny balls of densely packed protein found in the human brain and believed by Nymox scientists to be a major cause of senile plaques. Senile plaques are found abundantly in the brains of patients with Alzheimer's disease and are believed by many researchers to play a pivotal role in the fatal illness. Nymox has used spheron-based drug screening methods to discover, develop and test unique drug candidates aimed at limiting the formation of Alzheimer plaques from spherons and thus slowing or stopping the progression of the disease.
Another Nymox AD program targets neural thread protein (NTP), the brain protein measured by AlzheimAlert(TM), the Company's urine based diagnostic aid for AD. AlzheimAlert(TM) is currently available in Europe as a kit with the CE Mark and in the US as a CLIA certified clinical reference laboratory test service. Nymox has developed new drug candidates designed to inhibit the effects of over-production of NTP in the AD brain.
Other news from the department research and development
